UNOMR

UNOMR solves one of medicine’s biggest blind spots: the inability to fully read, or sequence, proteins, which govern every biological process. Its silicon‑based nanopore sensor platform, coupled with specialised consumables, data analysis and an Access Lab offering, delivers unprecedented protein insights for pharma, biotech and medical food companies and lays the foundation for the next wave of medical innovation and longevity advances. Built as an ETH Zurich spin‑off on more than five years of proprietary research and patented technology, UNOMR is now running pilots with early‑access devices and seeking collaborators to test the platform on site.